OCS-05 +SoC (corticosteroid) IV administration
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Optic Neuritis
Conditions
Optic Neuritis
Trial Timeline
Feb 10, 2021 → Sep 16, 2024
NCT ID
NCT04762017About OCS-05 +SoC (corticosteroid) IV administration
OCS-05 +SoC (corticosteroid) IV administration is a phase 2 stage product being developed by Oculis Holding AG for Optic Neuritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04762017. Target conditions include Optic Neuritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04762017 | Phase 2 | Completed |
Competing Products
20 competing products in Optic Neuritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| Atacicept + Placebo matched to atacicept | Merck | Phase 2 | 52 |
| Fingolimod 0.5mg/daily + Placebo | Novartis | Phase 2 | 52 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| Zyvox - linezolid + Matched control | Pfizer | Phase 3 | 76 |
| Dexmedetomidine HCL Injection + Placebo | Pfizer | Phase 3 | 76 |
| No intervention | Pfizer | Pre-clinical | 22 |
| Efgartigimod Alfa + Placebo | Argenx | Phase 2 | 49 |
| Diagnostic procedures | Bayer | Approved | 82 |
| Placebo + BIIB033 100mg/Kg | Biogen | Phase 2 | 49 |
| BIIB033 (anti-LINGO-1 mAb) + Placebo | Biogen | Phase 2 | 49 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |
| EVO756 + EVO756 + EVO756 + Placebo control | Evommune | Phase 2 | 47 |